Cyclo Therapeutics Merges with Applied Molecular Transport; Combined Company to Operate as Cyclo Therapeutics, Inc.

Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.

February 3, 2026

Pharmaceuticals

Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.

Atomic Transport Acquires Modern Transport Solutions

January 23, 2025

Environmental Services

Atomic Transport, a Chattanooga-based bulk-material transport and transfer-station operator, has acquired Modern Transport Solutions, which operates transfer and transportation services in Arizona and Colorado. The deal closed January 23, 2025 and expands Atomic's geographic footprint and service capabilities to better serve nationwide customers.

TeamBest Global Consolidates Best ABT Molecular Imaging and Best Cyclotron Systems into Best Cyclotron Systems, Inc.

January 1, 2022

Medical Devices

TeamBest Global Companies merged Best ABT Molecular Imaging and Best Cyclotron Systems effective January 1, 2022, consolidating the two affiliates under the name Best Cyclotron Systems, Inc. The combined business is headquartered in Springfield, Virginia, with manufacturing operations in Knoxville (TN), Loves Park (IL), Ottawa (ON), Vancouver (BC) and Dijon (France), and will expand its cyclotron manufacturing and radiopharmaceutical production capabilities.

J.F. Lehman & Company Acquires Atomic Transport

February 20, 2025

Environmental Services

J.F. Lehman & Company (through an investment affiliate) has acquired Atomic Transport, a Chattanooga-based specialized waste transport and transfer station management company. Comvest Partners (Comvest Credit Opportunities) sold its stake in Atomic; Atomic founders and management rolled equity and will continue to lead the business as JFLCO supports growth initiatives across the company's 30 terminals in 19 states.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.